Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy

Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy

Hepatocellular carcinoma (HCC), one of the most common and lethal tumors worldwide, is usually not diagnosed until the disease is advanced, which results in ineffective intervention and unfavorable prognosis. Small molecule targeted drugs of HCC, such as sorafenib, provided only about 2.8 months of...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Shao-Li Huang, Yu-Ming Wang, Quan-Yue Wang, Guang-Gui Feng, Fu-Qing Wu, Liu-Ming Yang, Xi-He Zhang, Hong-Wu Xin
Format: Artykuł
Język:English
Wydane: Frontiers Media S.A. 2021-07-01
Seria:Frontiers in Genetics
Hasła przedmiotowe:
hepatocellular carcinoma
immunotherapy
bispecific T-cell Engagers
bispecific antibody
aptamer
vascular endothelial growth factor (VEGF)
Dostęp online:https://www.frontiersin.org/articles/10.3389/fgene.2021.691391/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2021.691391/full

Podobne zapisy